Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Tuesday after market close. Here’s what ...

Myriad Genetics (MYG) lost ~20% on Wednesday, on track to record its worst one-day decline in a year, after the molecular ...

Myriad Health: All-in-one platform automatically calculates patient portions from a simple insurance card photo, generating compliant GFEs instantly MediPay + MedBill: Provides live eligibility checks ...

Myriad Genetics (NASDAQ:MYGN) reported first-quarter fiscal 2026 revenue of $200.4 million, reflecting 2% year-over-year ...

"We are reaffirming our full year 2026 financial guidance, including revenue of $860 million to $880 million, adjusted gross margin of 68% to 69% and adjusted EBITDA of $37 million to $49 million" ...

Myriad Genetics Inc. (NASDAQ:MYGN) shares rallied 35.7%, to $5.25 in after-hours trading on Tuesday following second-quarter results that exceeded analyst expectations and raised full-year revenue ...

Across the recent three months, 4 analysts have shared their insights on Myriad Genetics (NASDAQ:MYGN), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...

Samraat Raha, President and CEO, emphasized progress in high-growth market segments, citing "fourth quarter revenue of $210 million, coming in above the high end of the preannounced range" and ...

Sep 21, 2020 South San Francisco / CA / USA - Myriad headquarters in Silicon Valley; Myriad Genetics, Inc. is an American molecular diagnostic company UNITED STATES - APRIL 15, 2013: Lisa Schlager ...